Italy · Delayed Price · Currency is EUR Farmacosmo Statistics
Total Valuation
Farmacosmo has a market cap or net worth of EUR 16.22 million. The enterprise value is 22.43 million.
| Market Cap | 16.22M |
| Enterprise Value | 22.43M |
Important Dates
The next estimated earnings date is Tuesday, December 29, 2026.
| Earnings Date | Dec 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Farmacosmo has 38.81 million shares outstanding.
| Current Share Class | 34.72M |
| Shares Outstanding | 38.81M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 2.24% |
| Owned by Institutions (%) | 3.70% |
| Float | 33.85M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.35 |
| PB Ratio | 3.66 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 6.53 |
| P/OCF Ratio | 6.47 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.48 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 9.06 |
Financial Position
The company has a current ratio of 0.70, with a Debt / Equity ratio of 1.55.
| Current Ratio | 0.70 |
| Quick Ratio | 0.35 |
| Debt / Equity | 1.55 |
| Debt / EBITDA | n/a |
| Debt / FCF | 2.77 |
| Interest Coverage | -4.25 |
Financial Efficiency
Return on equity (ROE) is -42.68% and return on invested capital (ROIC) is -46.04%.
| Return on Equity (ROE) | -42.68% |
| Return on Assets (ROA) | -11.62% |
| Return on Invested Capital (ROIC) | -46.04% |
| Return on Capital Employed (ROCE) | -76.47% |
| Weighted Average Cost of Capital (WACC) | 8.51% |
| Revenue Per Employee | 811,036 |
| Profits Per Employee | -41,126 |
| Employee Count | 87 |
| Asset Turnover | 1.77 |
| Inventory Turnover | 6.25 |
Taxes
In the past 12 months, Farmacosmo has paid 374,658 in taxes.
| Income Tax | 374,658 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -6.49% in the last 52 weeks. The beta is 0.40, so Farmacosmo's price volatility has been lower than the market average.
| Beta (5Y) | 0.40 |
| 52-Week Price Change | -6.49% |
| 50-Day Moving Average | 0.47 |
| 200-Day Moving Average | 0.49 |
| Relative Strength Index (RSI) | 32.95 |
| Average Volume (20 Days) | 23,014 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Farmacosmo had revenue of EUR 46.23 million and -2.34 million in losses. Loss per share was -0.06.
| Revenue | 46.23M |
| Gross Profit | -1.91M |
| Operating Income | -4.87M |
| Pretax Income | -2.21M |
| Net Income | -2.34M |
| EBITDA | -4.03M |
| EBIT | -4.87M |
| Loss Per Share | -0.06 |
Balance Sheet
The company has 599,593 in cash and 6.79 million in debt, with a net cash position of -6.19 million or -0.16 per share.
| Cash & Cash Equivalents | 599,593 |
| Total Debt | 6.79M |
| Net Cash | -6.19M |
| Net Cash Per Share | -0.16 |
| Equity (Book Value) | 4.37M |
| Book Value Per Share | 0.11 |
| Working Capital | -5.19M |
Cash Flow
In the last 12 months, operating cash flow was 2.47 million and capital expenditures -21,748, giving a free cash flow of 2.45 million.
| Operating Cash Flow | 2.47M |
| Capital Expenditures | -21,748 |
| Depreciation & Amortization | 835,327 |
| Net Borrowing | -1.13M |
| Free Cash Flow | 2.45M |
| FCF Per Share | 0.06 |
Margins
Gross margin is -4.14%, with operating and profit margins of -10.52% and -5.07%.
| Gross Margin | -4.14% |
| Operating Margin | -10.52% |
| Pretax Margin | -4.78% |
| Profit Margin | -5.07% |
| EBITDA Margin | -8.72% |
| EBIT Margin | -10.52% |
| FCF Margin | 5.30% |
Dividends & Yields
This stock pays an annual dividend of 0.01, which amounts to a dividend yield of 2.39%.
| Dividend Per Share | 0.01 |
| Dividend Yield | 2.39% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | 2.43% |
| Earnings Yield | -14.66% |
| FCF Yield | 15.32% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
| Price Target | 0.99 |
| Price Target Difference | 136.84% |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | -0.65% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Farmacosmo has an Altman Z-Score of 0.84 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.84 |
| Piotroski F-Score | 3 |